First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer.
Morgensztern D, Ready N, Johnson M, Dowlati A, Choudhury N, Carbone D, Schaefer E, Arnold S, Puri S, Piotrowska Z, Hegde A, Chiang A, Iams W, Tolcher A, Nosaki K, Zha J, Li R, Hingorani P, Jeng E, Furqan M. First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer. Journal Of Clinical Oncology 2023, 41: 3002-3002. DOI: 10.1200/jco.2023.41.16_suppl.3002.Peer-Reviewed Original ResearchSmall cell lung cancerTreatment-emergent adverse eventsClinical benefit rateMaximum tolerated doseAntibody-drug conjugatesCell lung cancerDose escalationMedian durationLung cancerProgrammed cell death-1 inhibitorRelapsed/refractory small cell lung cancerSmall cell lung cancer tumorsConfirmed objective response rateMedian duration of responseRecommended phase 2 doseModels of small cell lung cancerMedian duration of treatmentVeno-occlusive liver diseaseFirst-in-human studyAntitumor activityObjective response rateDose-limiting toxicityProgression-free survivalDuration of responseDuration of treatment